Cargando…

Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS

Alveolar epithelial–capillary barrier disruption is a hallmark of acute respiratory distress syndrome (ARDS). Contribution of mitochondrial dysfunction to the compromised alveolar-capillary barrier in ARDS remains unclear. Mesenchymal stromal cells-derived extracellular vesicles (MSC-EVs) are consid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dutra Silva, Johnatas, Su, Yue, Calfee, Carolyn S., Delucchi, Kevin L., Weiss, Daniel, McAuley, Danny F., O'Kane, Cecilia, Krasnodembskaya, Anna D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318599/ https://www.ncbi.nlm.nih.gov/pubmed/33334945 http://dx.doi.org/10.1183/13993003.02978-2020

Ejemplares similares

Mesenchymal stromal cells-derived extracellular vesicles reprogramme macrophages in ARDS models through the miR-181a-5p-PTEN-pSTAT5-SOCS1 axis
por: Su, Yue, et al.
Publicado: (2023)

Hypercapnic acidosis induces mitochondrial dysfunction and impairs the ability of mesenchymal stem cells to promote distal lung epithelial repair
por: Fergie, Nicola, et al.
Publicado: (2019)

Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS
por: Jackson, Megan V., et al.
Publicado: (2016)

Evidence for chemokine synergy during neutrophil migration in ARDS
por: Williams, Andrew E, et al.
Publicado: (2017)

Emerging pharmacological therapies for ARDS: COVID-19 and beyond
por: Horie, Shahd, et al.
Publicado: (2020)

Hyperoxaemia and hypoxaemia are associated with harm in patients with ARDS
por: Boyle, Andrew J., et al.
Publicado: (2021)

0995. Aspirin reduces neutrophilic pulmonary inflammation in a human model of acute respiratory distress syndrome induced by inhaled lipopolysaccharide
por: Hamid, U Imran, et al.
Publicado: (2014)

Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials
por: Santhakumaran, Shalini, et al.
Publicado: (2019)

Acute Respiratory Distress Syndrome Subphenotypes beyond the Syndrome: A Step toward Treatable Traits?
por: Reddy, Kiran, et al.
Publicado: (2021)

Do Nonventilatory Strategies for Acute Lung Injury and ARDS Work?
por: Sweeney, Rob Mac, et al.
Publicado: (2010)

Promises and challenges of personalized medicine to guide ARDS therapy
por: Wick, Katherine D., et al.
Publicado: (2021)

Comparison of machine learning clustering algorithms for detecting heterogeneity of treatment effect in acute respiratory distress syndrome: A secondary analysis of three randomised controlled trials
por: Sinha, Pratik, et al.
Publicado: (2021)

Respiratory Infections Cause the Release of Extracellular Vesicles: Implications in Exacerbation of Asthma/COPD
por: Eltom, Suffwan, et al.
Publicado: (2014)

The relationship between plasma cystatin C, mortality and acute respiratory distress syndrome subphenotype in the HARP-2 trial
por: McKelvey, Michael C., et al.
Publicado: (2023)

Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial
por: Boyle, Andrew James, et al.
Publicado: (2022)

Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials
por: Pienkos, Shaun M., et al.
Publicado: (2023)

ARDS Subphenotypes: Understanding a Heterogeneous Syndrome
por: Wilson, Jennifer G., et al.
Publicado: (2020)

Towards a biological definition of ARDS: are treatable traits the solution?
por: Bos, Lieuwe D. J., et al.
Publicado: (2022)

Mesenchymal stem cell‐derived extracellular vesicles for the treatment of acute respiratory distress syndrome
por: Abraham, Aswin, et al.
Publicado: (2019)

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
por: Zarrabi, Morteza, et al.
Publicado: (2023)

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study
por: Sinha, Pratik, et al.
Publicado: (2020)

Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis
por: Boyle, Andrew J, et al.
Publicado: (2015)

Prevention of post-operative complications by using a HMG-CoA reductase inhibitor in patients undergoing one-lung ventilation for non-cardiac surgery: study protocol for a randomised controlled trial
por: Shyamsundar, Murali, et al.
Publicado: (2018)

Cytokine adsorption during ECMO for COVID-19-related ARDS
por: Shekar, Kiran, et al.
Publicado: (2021)

Pharmacological treatments in ARDS; a state-of-the-art update
por: Boyle, Andrew James, et al.
Publicado: (2013)

Therapeutic effects of adipose-tissue-derived mesenchymal stromal cells and their extracellular vesicles in experimental silicosis
por: Bandeira, Elga, et al.
Publicado: (2018)

Mesenchymal stromal cell derived extracellular vesicles rescue radiation damage to murine marrow hematopoietic cells
por: Wen, Sicheng, et al.
Publicado: (2016)

Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system
por: Bailey, Melanie, et al.
Publicado: (2023)

Effects of mesenchymal stromal cell-derived extracellular vesicles in acute respiratory distress syndrome (ARDS): Current understanding and future perspectives
por: Su, Yue, et al.
Publicado: (2021)

A Porcine Ex Vivo Lung Perfusion Model To Investigate Bacterial Pathogenesis
por: Dumigan, Amy, et al.
Publicado: (2019)

Extracellular Vesicles in ARDS: New Insights into Pathogenesis with Novel Clinical Applications
por: Mahida, R. Y., et al.
Publicado: (2019)

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial
por: Gorman, Ellen, et al.
Publicado: (2021)

Nebulised mesenchymal stem cell derived extracellular vesicles ameliorate E. coli induced pneumonia in a rodent model
por: Gonzalez, Hector, et al.
Publicado: (2023)

Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury
por: McAuley, Daniel F, et al.
Publicado: (2013)

Diagnostic workup for ARDS patients
por: Papazian, Laurent, et al.
Publicado: (2016)

Mesenchymal Stromal Cells Are More Effective Than Their Extracellular Vesicles at Reducing Lung Injury Regardless of Acute Respiratory Distress Syndrome Etiology
por: Silva, Johnatas D., et al.
Publicado: (2019)

Understanding the Role of Mesenchymal Stromal Cells in Treating COVID-19 Acute Respiratory Distress Syndrome
por: O’Kane, Cecilia M., et al.
Publicado: (2022)

Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities
por: Moradinasab, Susan, et al.
Publicado: (2021)

Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol
por: Cross, Laurence JM, et al.
Publicado: (2013)

Effective and Safe Use of Glucocorticosteroids for Rescue of Late ARDS
por: Diana, Paolo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c92smvlvhguoqbc18np3ojd61j